Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 8466

  • The following term was ignored: (
  • See the search details.
1.

Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.

Szturz P, Vermorken JB.

Oral Oncol. 2019 Dec 11;101:104492. doi: 10.1016/j.oraloncology.2019.104492. [Epub ahead of print]

PMID:
31837576
2.

Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer.

Doumas S, Foukas PG, Economopoulou P, Kotsantis I, Psyrri A.

Oral Oncol. 2019 Dec 10;100:104477. doi: 10.1016/j.oraloncology.2019.104477. [Epub ahead of print] Review.

PMID:
31837533
3.

Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.

Yan R, Li J, Zhou Y, Yao L, Sun R, Xu Y, Ge Y, An G.

Life Sci. 2019 Dec 11:117150. doi: 10.1016/j.lfs.2019.117150. [Epub ahead of print]

PMID:
31837335
4.

Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.

Liu Y, Zheng P.

Trends Pharmacol Sci. 2019 Dec 10. pii: S0165-6147(19)30263-9. doi: 10.1016/j.tips.2019.11.003. [Epub ahead of print] Review.

PMID:
31836191
5.

Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes.

Imyanitov EN, Ekatherina K.

Expert Rev Mol Diagn. 2019 Dec 13. doi: 10.1080/14737159.2020.1705157. [Epub ahead of print]

PMID:
31835926
6.

Optimizing immunotherapy for gynecologic cancers.

Rubinstein MM, Makker V.

Curr Opin Obstet Gynecol. 2019 Dec 10. doi: 10.1097/GCO.0000000000000603. [Epub ahead of print]

PMID:
31833942
7.

Medical treatment of advanced cutaneous squamous-cell carcinoma.

Gellrich FF, Hüning S, Beissert S, Eigentler T, Stockfleth E, Gutzmer R, Meier F.

J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:38-43. doi: 10.1111/jdv.16024. Review.

PMID:
31833610
8.

Comparison of guidelines for the management of patients with high-risk and advanced cutaneous squamous cell carcinoma - a systematic review.

Heppt MV, Steeb T, Berking C, Nast A.

J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:25-32. doi: 10.1111/jdv.15846. Review.

PMID:
31833609
9.

Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma.

Shepherd ARH, Joshi R, Tan CP, Cohen P, Brook NR.

ANZ J Surg. 2019 Dec 12. doi: 10.1111/ans.15608. [Epub ahead of print] No abstract available.

PMID:
31833177
10.

Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange.

Chung M, Jaffer M, Verma N, Mokhtari S, Ramsakal A, Peguero E.

J Neurol. 2019 Dec 13. doi: 10.1007/s00415-019-09666-6. [Epub ahead of print]

PMID:
31832829
11.

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12.

PMID:
31832578
12.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.

Zeng X, Wan X, Peng L, Peng Y, Ma F, Liu Q, Tan C.

BMJ Open. 2019 Dec 11;9(12):e031019. doi: 10.1136/bmjopen-2019-031019.

PMID:
31831534
13.

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.

Liu X, Xu J, Zhang B, Liu J, Liang C, Meng Q, Hua J, Yu X, Shi S.

Mol Cancer. 2019 Dec 13;18(1):184. doi: 10.1186/s12943-019-1117-9. Review.

PMID:
31831007
14.

Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?

Califano R, Gomes F, Ackermann CJ, Rafee S, Tsakonas G, Ekman S.

Eur J Cancer. 2019 Dec 9;125:1-11. doi: 10.1016/j.ejca.2019.11.010. [Epub ahead of print] Review.

PMID:
31830688
15.

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.

Wang R, Zheng J, Shao X, Ishii Y, Roy A, Bello A, Lee R, Zhang J, Wind-Rotolo M, Feng Y.

J Immunother Cancer. 2019 Dec 11;7(1):348. doi: 10.1186/s40425-019-0819-2.

PMID:
31829287
16.

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.

Kitadai R, Okuma Y, Hakozaki T, Hosomi Y.

J Cancer Res Clin Oncol. 2019 Dec 11. doi: 10.1007/s00432-019-03104-w. [Epub ahead of print]

PMID:
31828427
17.

Investigation of the Ototoxic Effect of Pembrolizumab Using a Rat Model.

Kuzucu İ, Baklacı D, Guler İ, Uçaryılmaz EÖ, Kum RO, Özcan M.

Cureus. 2019 Nov 2;11(11):e6057. doi: 10.7759/cureus.6057.

PMID:
31827988
18.

Elevated expression of miR-146a correlates with high levels of immune cell exhaustion markers and suppresses cellular immune function in chronic HIV-1-infected patients.

Yu T, Ju Z, Luo M, Hu R, Teng Y, Xie L, Zhong C, Chen L, Hou W, Xiong Y, Feng Y.

Sci Rep. 2019 Dec 11;9(1):18829. doi: 10.1038/s41598-019-55100-2.

PMID:
31827152
20.

A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.

Xu Y, Wu Y, Zhang S, Ma P, Jin X, Wang Z, Yao M, Zhang E, Tao B, Qin Y, Chen H, Liu A, Chen M, Xiao M, Lu C, Mao R, Fan Y.

Cell Rep. 2019 Dec 10;29(11):3435-3447.e4. doi: 10.1016/j.celrep.2019.10.093.

PMID:
31825827

Supplemental Content

Loading ...
Support Center